Aleksander Midera
Aleksander Midera has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Anna Maria Zakrzewska
Central Clinical Hospital of the Medical University of Łódź, Łódź, Poland
9 shared publications - Julia Agnieszka Michalak
Independent Public Healthcare Center, Kościan, Poland
9 shared publications - Julia Aleksandra Leśniak
Central Clinical Hospital of the Medical University of Łódź, Pomorska 251, 92-213 Łódź, Poland
9 shared publications - Kinga Popielarska
Medical University of Gdansk, Gdansk, Poland
9 shared publications - Klaudia Elżbieta Niwińska
Independent Public Clinical Hospital named after Prof. W. Orłowski (CMKP), Warszawa, Poland
9 shared publications - Michał Borowski
Independent Public Healthcare Center, Mińsk Mazowiecki, Poland
9 shared publications
Latest Publications
- Open Access
- 4 May 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (2(50))
SELECTED BIOMARKERS IN SEPSIS: IL-6, sTREM-1 AND NEUTROPHIL CD64 - A LITERATURE REVIEW
Background: Sepsis is a life-threatening condition characterised by organ dysfunction caused by a dysregulated host response to infection and remains a major cause of morbidity and mortality worldwide. Early recognition is clinically challenging because initial symptoms are non-specific and commonly used inflammatory markers have limited diagnostic performance. Consequently, there is ongoing interest in biomarkers that enable faster and more accurate identification of sepsis. Aim: To discuss selected sepsis biomarkers: interleukin-6 (IL-6), soluble TREM-1 (sTREM-1), and neutrophil CD64 expression, with particular emphasis on biological mechanisms, clinical utility, and diagnostic limitations. Materials and methods: A narrative review of the literature was undertaken. Publications from 2016 to 2025 indexed in PubMed/MEDLINE, Scopus, and Google Scholar were analysed, including clinical studies, reviews, and meta-analyses. Evidence was assessed with respect to biological mechanisms, diagnostic and prognostic performance, and limitations of the biomarkers. Results: Neutrophil CD64 expression shows high specificity for bacterial infection and sepsis; however, routine use is constrained by limited assay standardisation and the absence of validated cut-off values. IL-6 rises very early and has prognostic value, correlating with the severity of organ dysfunction and mortality risk, but it has low specificity. sTREM-1 reflects activation of the TREM-1 axis and the intensity of the inflammatory response; however, its ability to distinguish sepsis from non-infectious SIRS is limited. Conclusions: None of the reviewed biomarkers should be used as a stand-alone diagnostic test. The greatest clinical value is likely to be achieved with a multiparametric approach that combines clinical assessment and organ dysfunction scores with biomarkers representing different stages of the immune response. This strategy may improve early recognition, risk stratification, and monitoring of sepsis.
- 4 May 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (2(50))
Open AccessSELECTED BIOMARKERS IN SEPSIS: IL-6, sTREM-1 AND NEUTROPHIL CD64 - A LITERATURE REVIEW
Background: Sepsis is a life-threatening condition characterised by organ dysfunction caused by a dysregulated host response to infection and remains a major cause of morbidity and mortality worldwide. Early recognition is clinically challenging because initial symptoms are non-specific and commonly used inflammatory markers have limited diagnostic performance. Consequently, there is ongoing interest in biomarkers that enable faster and more accurate identification of sepsis. Aim: To discuss selected sepsis biomarkers: interleukin-6 (IL-6), soluble TREM-1 (sTREM-1), and neutrophil CD64 expression, with particular emphasis on biological mechanisms, clinical utility, and diagnostic limitations. Materials and methods: A narrative review of the literature was undertaken. Publications from 2016 to 2025 indexed in PubMed/MEDLINE, Scopus, and Google Scholar were analysed, including clinical studies, reviews, and meta-analyses. Evidence was assessed with respect to biological mechanisms, diagnostic and prognostic performance, and limitations of the biomarkers. Results: Neutrophil CD64 expression shows high specificity for bacterial infection and sepsis; however, routine use is constrained by limited assay standardisation and the absence of validated cut-off values. IL-6 rises very early and has prognostic value, correlating with the severity of organ dysfunction and mortality risk, but it has low specificity. sTREM-1 reflects activation of the TREM-1 axis and the intensity of the inflammatory response; however, its ability to distinguish sepsis from non-infectious SIRS is limited. Conclusions: None of the reviewed biomarkers should be used as a stand-alone diagnostic test. The greatest clinical value is likely to be achieved with a multiparametric approach that combines clinical assessment and organ dysfunction scores with biomarkers representing different stages of the immune response. This strategy may improve early recognition, risk stratification, and monitoring of sepsis.
- Open Access
- 16 April 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (2(50))
ORAL MANIFESTATIONS OF AMYLOIDOSIS AS AN EARLY INDICATOR OF THE DISEASE - A LITERATURE REVIEW
Introduction and Purpose: Amyloidosis is a rare group of diseases characterized by the irreversible extracellular deposition of insoluble amyloid fibrils in various organs and tissues. Treatment should begin as early as possible, immediately following diagnosis. Therefore, clinicians should be aware of the disease’s characteristic features, including those visible in the oral cavity- which will be the focus of this article. While systemic manifestations are often emphasized, changes in the oral cavity can serve as early- and sometimes the first- indicators of the disease. The aim of this article is to present the most relevant and recent scientific reports from the past ten years regarding oral manifestations of amyloidosis, highlight their diagnostic value, and emphasize the role of the dental professionals in the multidisciplinary approach to early detection and patient care. Description of the State of Knowledge: Recent literature highlights a broad range of oral manifestations in amyloidosis, including macroglossia, nodular lesions, hemorrhagic changes, and chronic ulcers- some of which may appear without systemic symptoms. Histopathological biopsy with Congo red staining remains the gold standard for confirming amyloid deposits. Case reports increasingly show that oral findings can prompt systemic evaluation, leading to earlier diagnosis and management. This underscores the importance of dental professionals in recognizing subtle signs and initiating appropriate referrals. Conclusions: Oral signs of amyloidosis can be the first clue to a systemic disease. Recognizing the type and location of lesions helps assess whether the disease is localized or systemic. Early diagnosis may improve outcomes- and in some cases, even save the patient’s life.
- 16 April 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (2(50))
Open AccessORAL MANIFESTATIONS OF AMYLOIDOSIS AS AN EARLY INDICATOR OF THE DISEASE - A LITERATURE REVIEW
Introduction and Purpose: Amyloidosis is a rare group of diseases characterized by the irreversible extracellular deposition of insoluble amyloid fibrils in various organs and tissues. Treatment should begin as early as possible, immediately following diagnosis. Therefore, clinicians should be aware of the disease’s characteristic features, including those visible in the oral cavity- which will be the focus of this article. While systemic manifestations are often emphasized, changes in the oral cavity can serve as early- and sometimes the first- indicators of the disease. The aim of this article is to present the most relevant and recent scientific reports from the past ten years regarding oral manifestations of amyloidosis, highlight their diagnostic value, and emphasize the role of the dental professionals in the multidisciplinary approach to early detection and patient care. Description of the State of Knowledge: Recent literature highlights a broad range of oral manifestations in amyloidosis, including macroglossia, nodular lesions, hemorrhagic changes, and chronic ulcers- some of which may appear without systemic symptoms. Histopathological biopsy with Congo red staining remains the gold standard for confirming amyloid deposits. Case reports increasingly show that oral findings can prompt systemic evaluation, leading to earlier diagnosis and management. This underscores the importance of dental professionals in recognizing subtle signs and initiating appropriate referrals. Conclusions: Oral signs of amyloidosis can be the first clue to a systemic disease. Recognizing the type and location of lesions helps assess whether the disease is localized or systemic. Early diagnosis may improve outcomes- and in some cases, even save the patient’s life.
- Open Access
- 25 March 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 4 (1(49))
SLEEP DISORDERS AS A RISK FACTOR FOR CARDIOVASCULAR DISEASE: A COMPREHENSIVE REVIEW
Background. Sleep disorders represent a heterogeneous group of conditions that impair sleep quality, duration, and architecture, leading to significant daytime dysfunction and increased global morbidity. Epidemiological data indicate that approximately 30–40% of adults experience sleep disturbances, including insomnia and obstructive sleep apnea (OSA), which are increasingly recognized as modifiable risk factors for cardiovascular disease (CVD). Aim. The aim of this narrative review was to synthesize current evidence on the association between sleep disorders and major cardiovascular outcomes and to identify the biological mechanisms underlying these relationships. Material and methods. A narrative review of the literature was conducted using PubMed, ScienceDirect, JAMA Network, OUP, and open-access repositories. Epidemiological studies, cohort studies, and meta-analyses evaluating the impact of insomnia, sleep-disordered breathing, and circadian rhythm disturbances on hypertension, coronary artery disease, heart failure, arrhythmias, and stroke were analyzed. Results. The reviewed evidence demonstrates that insomnia and obstructive sleep apnea are consistently associated with an increased risk of cardiovascular diseases, particularly hypertension, atrial fibrillation, coronary artery disease, heart failure, and stroke. The underlying mechanisms include sympathetic nervous system overactivation, oxidative stress, systemic inflammation, endothelial dysfunction, and dysregulation of glucose and lipid metabolism. Conclusions. Sleep disorders have great effects on the cardiovascular system and should be considered independent, modifiable risk factors for CVD. Early diagnosis and treatment of sleep disorders may play a crucial role in cardiovascular disease prevention and risk reduction.
- 25 March 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 4 (1(49))
Open AccessSLEEP DISORDERS AS A RISK FACTOR FOR CARDIOVASCULAR DISEASE: A COMPREHENSIVE REVIEW
Background. Sleep disorders represent a heterogeneous group of conditions that impair sleep quality, duration, and architecture, leading to significant daytime dysfunction and increased global morbidity. Epidemiological data indicate that approximately 30–40% of adults experience sleep disturbances, including insomnia and obstructive sleep apnea (OSA), which are increasingly recognized as modifiable risk factors for cardiovascular disease (CVD). Aim. The aim of this narrative review was to synthesize current evidence on the association between sleep disorders and major cardiovascular outcomes and to identify the biological mechanisms underlying these relationships. Material and methods. A narrative review of the literature was conducted using PubMed, ScienceDirect, JAMA Network, OUP, and open-access repositories. Epidemiological studies, cohort studies, and meta-analyses evaluating the impact of insomnia, sleep-disordered breathing, and circadian rhythm disturbances on hypertension, coronary artery disease, heart failure, arrhythmias, and stroke were analyzed. Results. The reviewed evidence demonstrates that insomnia and obstructive sleep apnea are consistently associated with an increased risk of cardiovascular diseases, particularly hypertension, atrial fibrillation, coronary artery disease, heart failure, and stroke. The underlying mechanisms include sympathetic nervous system overactivation, oxidative stress, systemic inflammation, endothelial dysfunction, and dysregulation of glucose and lipid metabolism. Conclusions. Sleep disorders have great effects on the cardiovascular system and should be considered independent, modifiable risk factors for CVD. Early diagnosis and treatment of sleep disorders may play a crucial role in cardiovascular disease prevention and risk reduction.
- Open Access
- 16 March 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 3 (1(49))
INTERACTIONS BETWEEN GUT MICROBIOTA AND DEPRESSIVE AND ANXIETY DISORDERS: A COMPREHENSIVE REVIEW
Background. Depressive and anxiety disorders are major challenges in modern medicine and are increasingly linked to gut dysbiosis. Evidence indicates that affected patients often exhibit reduced microbial diversity, lower levels of SCFA-producing bacteria, and increased pro-inflammatory taxa. Proposed mechanisms include altered SCFA production, neurotransmitter modulation, vagus nerve signaling, immune activation, HPA axis dysregulation, and impaired gut and blood–brain barrier integrity Aim. This review summarizes current evidence on the gut-brain axis and how it impacts mood disorders. Material and methods. The review analyzed English-language studies published between 2015 and 2025 using PubMed, SpringerLink, and Elsevier, focusing primarily on human research examining the gut microbiota, gut–brain axis, and their association with depressive and anxiety disorders. Results. The review highlights the potential of microbiota-based therapies for mood disorders. Probiotics, especially psychobiotic strains, show the most consistent benefits in reducing depressive and anxiety symptoms, while evidence for prebiotics and dietary interventions remains limited. Current studies are constrained by methodological heterogeneity, small sample sizes, and short intervention durations. Conclusions. Overall, accumulating data support the gut microbiota as a significant contributor to the development and modulation of depressive and anxiety disorders. While definitive clinical recommendations cannot yet be made, microbiota modulation represents a promising avenue for future integrative treatment approaches and warrants further rigorous investigation.
- 16 March 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 3 (1(49))
Open AccessINTERACTIONS BETWEEN GUT MICROBIOTA AND DEPRESSIVE AND ANXIETY DISORDERS: A COMPREHENSIVE REVIEW
Background. Depressive and anxiety disorders are major challenges in modern medicine and are increasingly linked to gut dysbiosis. Evidence indicates that affected patients often exhibit reduced microbial diversity, lower levels of SCFA-producing bacteria, and increased pro-inflammatory taxa. Proposed mechanisms include altered SCFA production, neurotransmitter modulation, vagus nerve signaling, immune activation, HPA axis dysregulation, and impaired gut and blood–brain barrier integrity Aim. This review summarizes current evidence on the gut-brain axis and how it impacts mood disorders. Material and methods. The review analyzed English-language studies published between 2015 and 2025 using PubMed, SpringerLink, and Elsevier, focusing primarily on human research examining the gut microbiota, gut–brain axis, and their association with depressive and anxiety disorders. Results. The review highlights the potential of microbiota-based therapies for mood disorders. Probiotics, especially psychobiotic strains, show the most consistent benefits in reducing depressive and anxiety symptoms, while evidence for prebiotics and dietary interventions remains limited. Current studies are constrained by methodological heterogeneity, small sample sizes, and short intervention durations. Conclusions. Overall, accumulating data support the gut microbiota as a significant contributor to the development and modulation of depressive and anxiety disorders. While definitive clinical recommendations cannot yet be made, microbiota modulation represents a promising avenue for future integrative treatment approaches and warrants further rigorous investigation.
- Open Access
- 16 January 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 87, 67444
The Impact of GLP-1 Analogues and Tirzepatide on Female Fertility: Mechanisms, Clinical Evidence, and Implications
Obesity impairs female fertility through metabolic, endocrine and inflammatory pathways that disrupt ovulation, reduce oocyte competence and impair endometrial receptivity. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and the dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist tirzepatide have become highly effective therapies for weight management and metabolic optimisation, raising interest in their potential reproductive benefits. This narrative review synthesises current mechanistic and clinical evidence on how GLP-1 receptor agonists and tirzepatide may influence reproductive function in women of reproductive age. A literature search was conducted using PubMed, Scopus and Web of Science for peer-reviewed human studies and major reviews published up to December 2025 that evaluated metabolic, endocrine or reproductive outcomes. Available evidence suggests that GLP-1 signalling may influence the hypothalamic–pituitary–ovarian axis, adipokine pathways, oocyte mitochondrial function and endometrial gene expression. Clinical studies indicate that liraglutide and semaglutide improve body weight, insulin resistance and hyperandrogenism, leading to restoration of menstrual regularity and increased ovulation rates, with some reports of improved spontaneous conception and assisted reproduction outcomes. Tirzepatide provides greater metabolic benefits, although fertility-specific data remain limited. Overall, GLP-1–based therapies act primarily as metabolic optimisers that may secondarily enhance fertility, while evidence for direct reproductive effects and periconceptional safety remains insufficient.
- 16 January 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 87, 67444
Open AccessThe Impact of GLP-1 Analogues and Tirzepatide on Female Fertility: Mechanisms, Clinical Evidence, and Implications
Obesity impairs female fertility through metabolic, endocrine and inflammatory pathways that disrupt ovulation, reduce oocyte competence and impair endometrial receptivity. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and the dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist tirzepatide have become highly effective therapies for weight management and metabolic optimisation, raising interest in their potential reproductive benefits. This narrative review synthesises current mechanistic and clinical evidence on how GLP-1 receptor agonists and tirzepatide may influence reproductive function in women of reproductive age. A literature search was conducted using PubMed, Scopus and Web of Science for peer-reviewed human studies and major reviews published up to December 2025 that evaluated metabolic, endocrine or reproductive outcomes. Available evidence suggests that GLP-1 signalling may influence the hypothalamic–pituitary–ovarian axis, adipokine pathways, oocyte mitochondrial function and endometrial gene expression. Clinical studies indicate that liraglutide and semaglutide improve body weight, insulin resistance and hyperandrogenism, leading to restoration of menstrual regularity and increased ovulation rates, with some reports of improved spontaneous conception and assisted reproduction outcomes. Tirzepatide provides greater metabolic benefits, although fertility-specific data remain limited. Overall, GLP-1–based therapies act primarily as metabolic optimisers that may secondarily enhance fertility, while evidence for direct reproductive effects and periconceptional safety remains insufficient.
- Open Access
- 3 January 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 49
GLP-1 Analogues in Rheumatology - The Influence of Obesity on the Effectiveness of Biological Treatment
Obesity and overweight are becoming a global health challenge and are increasingly prevalent in patients with rheumatic diseases such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), and systemic lupus erythematosus (SLE). Adipose tissue serves as an active endocrine organ, secreting adipokines and proinflammatory cytokines, including leptin, tumor necrosis factor alpha (TNF-alpha), and interleukin 6 (IL-6). Obesity exacerbates inflammatory processes, increases the number of classically activated macrophages (M1) and reduces adiponectin levels, which may sustain and amplify the immune response typical of autoimmune diseases. Available studies indicate that obesity is associated with a lower likelihood of achieving minimal disease activity, particularly in RA and PsA. In RA patients, a higher body mass index (BMI) correlates with greater pain, a higher Health Assessment Questionnaire (HAQ) score, and a lower chance of remission, even with similar treatment. In the case of PsA, obesity increases the risk of disease onset. In SLE, a higher BMI is associated with increased disease activity and excessive fatigue. Research suggests that the effectiveness of TNF-alpha inhibitors may be reduced in patients with obesity, while the response to medications such as tocilizumab or abatacept is often independent of BMI. At the same time, abundant data confirm that weight loss brings tangible benefits – improving functional outcomes, and increasing the chance of achieving minimal disease activity, particularly in RA and PsA. Preliminary observations regarding Glucagon-Like Peptide-1 (GLP-1) agonists indicate their possible anti-inflammatory effects, although further research is needed. In summary, obesity significantly affects the course of rheumatic diseases and the effectiveness of therapy, and weight loss is an important element in supporting treatment.
- 3 January 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 49
Open AccessGLP-1 Analogues in Rheumatology - The Influence of Obesity on the Effectiveness of Biological Treatment
Obesity and overweight are becoming a global health challenge and are increasingly prevalent in patients with rheumatic diseases such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), and systemic lupus erythematosus (SLE). Adipose tissue serves as an active endocrine organ, secreting adipokines and proinflammatory cytokines, including leptin, tumor necrosis factor alpha (TNF-alpha), and interleukin 6 (IL-6). Obesity exacerbates inflammatory processes, increases the number of classically activated macrophages (M1) and reduces adiponectin levels, which may sustain and amplify the immune response typical of autoimmune diseases. Available studies indicate that obesity is associated with a lower likelihood of achieving minimal disease activity, particularly in RA and PsA. In RA patients, a higher body mass index (BMI) correlates with greater pain, a higher Health Assessment Questionnaire (HAQ) score, and a lower chance of remission, even with similar treatment. In the case of PsA, obesity increases the risk of disease onset. In SLE, a higher BMI is associated with increased disease activity and excessive fatigue. Research suggests that the effectiveness of TNF-alpha inhibitors may be reduced in patients with obesity, while the response to medications such as tocilizumab or abatacept is often independent of BMI. At the same time, abundant data confirm that weight loss brings tangible benefits – improving functional outcomes, and increasing the chance of achieving minimal disease activity, particularly in RA and PsA. Preliminary observations regarding Glucagon-Like Peptide-1 (GLP-1) agonists indicate their possible anti-inflammatory effects, although further research is needed. In summary, obesity significantly affects the course of rheumatic diseases and the effectiveness of therapy, and weight loss is an important element in supporting treatment.
- Open Access
- 2 January 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 49
Proton Pump Inhibitors - Clinical Use and Long-Term Safety in Adults
Background. Proton pump inhibitors (PPIs) are widely prescribed for gastrointestinal disorders. Their potent and persistent inhibition of gastric acid ensures efficacy but has raised concerns about adverse effects during long-term therapy. Aim. To summarize current evidence on the indications and clinical benefits of proton pump inhibitors in adults, and to review major long-term adverse effects and drug–drug interactions to guide safer treatment strategies. Material and methods. A narrative literature review was conducted using PubMed/MEDLINE for articles published between January 2016 and November 2025. Peer-reviewed human studies and major reviews on adults receiving oral PPIs were included if they addressed utilization, indications, duration of therapy, long-term adverse effects, drug-drug interactions, or deprescribing strategies. Pediatric studies, purely animal research, and non-peer-reviewed articles were excluded. Results. PPIs remain first-line treatment in gastroesophageal reflux disease, peptic ulcer disease, Helicobacter pylori eradication, and selected hypersecretory conditions. However, many patients receive these medications chronically without a clear ongoing indication or regular reassessment. Long-term PPI therapy can be linked to nutrient and electrolyte disturbances, increased fracture risk, renal complications, infections, and clinically relevant interactions with drugs such as clopidogrel and methotrexate. Cardiovascular and neurological risk signals remain inconclusive. Conclusions. PPIs should not be withheld from patients with justified indications, but must be prescribed thoughtfully. Clinicians need to use the lowest effective dose for the shortest necessary duration, regularly review indications, and educate patients to limit unnecessary chronic exposure while preserving the substantial benefits of PPI therapy.
- 2 January 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 49
Open AccessProton Pump Inhibitors - Clinical Use and Long-Term Safety in Adults
Background. Proton pump inhibitors (PPIs) are widely prescribed for gastrointestinal disorders. Their potent and persistent inhibition of gastric acid ensures efficacy but has raised concerns about adverse effects during long-term therapy. Aim. To summarize current evidence on the indications and clinical benefits of proton pump inhibitors in adults, and to review major long-term adverse effects and drug–drug interactions to guide safer treatment strategies. Material and methods. A narrative literature review was conducted using PubMed/MEDLINE for articles published between January 2016 and November 2025. Peer-reviewed human studies and major reviews on adults receiving oral PPIs were included if they addressed utilization, indications, duration of therapy, long-term adverse effects, drug-drug interactions, or deprescribing strategies. Pediatric studies, purely animal research, and non-peer-reviewed articles were excluded. Results. PPIs remain first-line treatment in gastroesophageal reflux disease, peptic ulcer disease, Helicobacter pylori eradication, and selected hypersecretory conditions. However, many patients receive these medications chronically without a clear ongoing indication or regular reassessment. Long-term PPI therapy can be linked to nutrient and electrolyte disturbances, increased fracture risk, renal complications, infections, and clinically relevant interactions with drugs such as clopidogrel and methotrexate. Cardiovascular and neurological risk signals remain inconclusive. Conclusions. PPIs should not be withheld from patients with justified indications, but must be prescribed thoughtfully. Clinicians need to use the lowest effective dose for the shortest necessary duration, regularly review indications, and educate patients to limit unnecessary chronic exposure while preserving the substantial benefits of PPI therapy.
- Open Access
- 2 January 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 49
Proton Pump Inhibitors - Clinical Use and Long-Term Safety in Adults
Background. Proton pump inhibitors (PPIs) are widely prescribed for gastrointestinal disorders. Their potent and persistent inhibition of gastric acid ensures efficacy but has raised concerns about adverse effects during long-term therapy. Aim. To summarize current evidence on the indications and clinical benefits of proton pump inhibitors in adults, and to review major long-term adverse effects and drug–drug interactions to guide safer treatment strategies. Material and methods. A narrative literature review was conducted using PubMed/MEDLINE for articles published between January 2016 and November 2025. Peer-reviewed human studies and major reviews on adults receiving oral PPIs were included if they addressed utilization, indications, duration of therapy, long-term adverse effects, drug-drug interactions, or deprescribing strategies. Pediatric studies, purely animal research, and non-peer-reviewed articles were excluded. Results. PPIs remain first-line treatment in gastroesophageal reflux disease, peptic ulcer disease, Helicobacter pylori eradication, and selected hypersecretory conditions. However, many patients receive these medications chronically without a clear ongoing indication or regular reassessment. Long-term PPI therapy can be linked to nutrient and electrolyte disturbances, increased fracture risk, renal complications, infections, and clinically relevant interactions with drugs such as clopidogrel and methotrexate. Cardiovascular and neurological risk signals remain inconclusive. Conclusions. PPIs should not be withheld from patients with justified indications, but must be prescribed thoughtfully. Clinicians need to use the lowest effective dose for the shortest necessary duration, regularly review indications, and educate patients to limit unnecessary chronic exposure while preserving the substantial benefits of PPI therapy.
- 2 January 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 49
Open AccessProton Pump Inhibitors - Clinical Use and Long-Term Safety in Adults
Background. Proton pump inhibitors (PPIs) are widely prescribed for gastrointestinal disorders. Their potent and persistent inhibition of gastric acid ensures efficacy but has raised concerns about adverse effects during long-term therapy. Aim. To summarize current evidence on the indications and clinical benefits of proton pump inhibitors in adults, and to review major long-term adverse effects and drug–drug interactions to guide safer treatment strategies. Material and methods. A narrative literature review was conducted using PubMed/MEDLINE for articles published between January 2016 and November 2025. Peer-reviewed human studies and major reviews on adults receiving oral PPIs were included if they addressed utilization, indications, duration of therapy, long-term adverse effects, drug-drug interactions, or deprescribing strategies. Pediatric studies, purely animal research, and non-peer-reviewed articles were excluded. Results. PPIs remain first-line treatment in gastroesophageal reflux disease, peptic ulcer disease, Helicobacter pylori eradication, and selected hypersecretory conditions. However, many patients receive these medications chronically without a clear ongoing indication or regular reassessment. Long-term PPI therapy can be linked to nutrient and electrolyte disturbances, increased fracture risk, renal complications, infections, and clinically relevant interactions with drugs such as clopidogrel and methotrexate. Cardiovascular and neurological risk signals remain inconclusive. Conclusions. PPIs should not be withheld from patients with justified indications, but must be prescribed thoughtfully. Clinicians need to use the lowest effective dose for the shortest necessary duration, regularly review indications, and educate patients to limit unnecessary chronic exposure while preserving the substantial benefits of PPI therapy.
- Open Access
- 28 December 2025
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 48
Zuranolone in Postpartum Depression: A Review of the First Oral Neurosteroid Treatment
Background: Postpartum depression (PPD) is a severe mood disorder affecting 1 in 7 postpartum women. It significantly impacts maternal functioning and infant development. SSRIs are currently the first-line treatment, but require 4-8 weeks to take effect and show variable efficacy. The neurosteroid hypothesis connects PPD symptoms to an abrupt drop in allopregnanolone after childbirth. Zuranolone, a synthetic modulator of the GABA-A receptor, is the first oral neurosteroid specifically indicated for postpartum depression. Aim: This review analyzes zuranolone’s pharmacology, Phase III clinical efficacy, and its practical use for postpartum depression. Material and methods: We conducted a comprehensive literature review using PubMed. Search terms included „zuranolone", „neurosteroid", and "postpartum depression”. We reviewed publications from 2015 to 2025, focusing on Phase III clinical studies, pharmacological analyses, and FDA/EMA regulatory documents. Results: Zuranolone is administered as 50 mg once daily for 14 days. Two Phase III randomized, placebo-controlled trials (n=150, n=196) evaluated zuranolone for moderate to severe postpartum depression. In the pivotal trial, the least-squares mean difference on the HAM-D was -4.0 versus placebo (95% CI: -6.3 to -1.7; p=0.001). Response rates were 57.0% versus 38.9% (p=0.021), and remission rates were 26.9% versus 16.7%. Effects were seen by day 3 and lasted through day 45. Conclusions: Zuranolone represents a significant therapeutic advance in the treatment of postpartum depression. It offers immediate symptom relief during the critical early postpartum period. Further research is needed to assess effectiveness and safety in a more heterogeneous population, as well as the long-term effects in mood disorders.
- 28 December 2025
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 48
Open AccessZuranolone in Postpartum Depression: A Review of the First Oral Neurosteroid Treatment
Background: Postpartum depression (PPD) is a severe mood disorder affecting 1 in 7 postpartum women. It significantly impacts maternal functioning and infant development. SSRIs are currently the first-line treatment, but require 4-8 weeks to take effect and show variable efficacy. The neurosteroid hypothesis connects PPD symptoms to an abrupt drop in allopregnanolone after childbirth. Zuranolone, a synthetic modulator of the GABA-A receptor, is the first oral neurosteroid specifically indicated for postpartum depression. Aim: This review analyzes zuranolone’s pharmacology, Phase III clinical efficacy, and its practical use for postpartum depression. Material and methods: We conducted a comprehensive literature review using PubMed. Search terms included „zuranolone", „neurosteroid", and "postpartum depression”. We reviewed publications from 2015 to 2025, focusing on Phase III clinical studies, pharmacological analyses, and FDA/EMA regulatory documents. Results: Zuranolone is administered as 50 mg once daily for 14 days. Two Phase III randomized, placebo-controlled trials (n=150, n=196) evaluated zuranolone for moderate to severe postpartum depression. In the pivotal trial, the least-squares mean difference on the HAM-D was -4.0 versus placebo (95% CI: -6.3 to -1.7; p=0.001). Response rates were 57.0% versus 38.9% (p=0.021), and remission rates were 26.9% versus 16.7%. Effects were seen by day 3 and lasted through day 45. Conclusions: Zuranolone represents a significant therapeutic advance in the treatment of postpartum depression. It offers immediate symptom relief during the critical early postpartum period. Further research is needed to assess effectiveness and safety in a more heterogeneous population, as well as the long-term effects in mood disorders.